GKN1 Specific Neutra™ Antibody Products

Are you struggling with low antibody specificity, inconsistent results in gastric biomarker studies, or delayed therapeutic development? Creative Biolabs' GKN1 specific Neutra™ antibody products empower your research with high-affinity, rigorously validated antibodies engineered through advanced phage display technology, enabling precise detection and functional modulation of GKN1 to accelerate drug discovery and mechanistic studies.

Introduction to GKN1

Gastrokine 1 (GKN1), a secreted protein predominantly expressed in gastric mucosal epithelial cells, plays a critical role in maintaining gastric homeostasis and mucosal repair. Its expression is tightly regulated under physiological conditions, serving as a protective agent against oxidative stress and microbial invasion.

• Structural Insights

GKN1 comprises a conserved BRICHOS domain essential for its molecular chaperone activity, facilitating proper protein folding and stability. The protein forms homodimers via disulfide bonds, a structural feature critical for its interaction with mucin proteins and other components of the gastric barrier. Recent crystallography studies reveal that its N-terminal region mediates binding to phosphatidylserine on cell membranes, while the C-terminal region participates in extracellular matrix remodeling.

Fig.1 GKN1 gene inactivation proposed mechanisms.¹

• Signaling Pathways and Functional Roles

GKN1 modulates key pathways, including the PI3K/AKT and NF-κB cascades, to regulate epithelial cell proliferation and apoptosis. It suppresses Helicobacter pylori-induced inflammation by inhibiting TLR4/MyD88 signaling, thereby protecting against gastric lesions. Additionally, GKN1 interacts with trefoil factor family peptides to enhance mucosal healing, making it a central mediator in gastrointestinal repair mechanisms.

• Disease Associations

Dysregulation of GKN1 is implicated in gastric carcinogenesis, chronic gastritis, and peptic ulcer disease. Its downregulation correlates with poor prognosis in diffuse-type gastric cancers, while overexpression is observed in early-stage mucosal injury, suggesting its dual role as a biomarker and therapeutic target.

Applications of Anti-GKN1 Neutralizing Antibodies

• Diagnostic Biomarker Development

Anti-GKN1 antibodies are instrumental in developing non-invasive assays for early gastric cancer detection. By quantifying GKN1 levels in serum, researchers can stratify patients at risk of malignancy or monitor treatment responses.

• Therapeutic Target Validation

These antibodies allow functional knockout of GKN1 in preclinical models, clarifying its oncogenic or tumor-suppressive roles. Neutralizing GKN1 in xenograft studies has shown reduced tumor growth and metastasis in HER2-positive gastric cancers.

• Mechanistic Studies in Mucosal Repair

In vitro neutralization experiments reveal that GKN1 blockade delays epithelial restitution, underscoring its necessity in wound healing. This application is vital for studying Barrett's esophagus and chemotherapy-induced mucositis.

• Host-Pathogen Interaction Research

Anti-GKN1 antibodies inhibit H. pylori adhesion to gastric cells, providing insights into bacterial colonization mechanisms and guiding antimicrobial strategies.

Our Anti-GKN1 Neutralizing Antibodies

Creative Biolabs' anti-GKN1 antibodies are developed using hybridoma technology, ensuring exceptional specificity and batch-to-batch consistency. These antibodies enable:

- Quantitative Detection: Reliable measurement of GKN1 levels in serum and tissue lysates via ELISA and Western blot (detection limit: 0.1 ng/mL).

- Functional Blockade: Neutralize GKN1 activity in vitro and in vivo, facilitating studies on its role in tumor progression and immune evasion.

- Tissue Localization: High-resolution imaging of GKN1 distribution in formalin-fixed paraffin-embedded (FFPE) samples using IHC (validated across human, mouse, and rat specimens).

Engineered for minimal cross-reactivity with GKN2 or other BRICHOS-domain proteins, these antibodies are optimized for flow cytometry, immunoprecipitation, and inhibitor screening.

Creative Biolabs' GKN1 specific Neutra™ antibody products are your gateway to breakthroughs in gastrointestinal disease research. With unmatched specificity and reproducibility, our antibodies are validated across diverse applications, from translational studies to high-throughput drug screening.

Contact our team today to discuss your project requirements and request customized solutions.

REFERENCE

1. Di Stadio, Chiara Stella, et al. "Down-regulation of GKN1 in gastric cancer is not associated with the RUNX3 expression." Journal of Biosciences and Medicines 5.11 (2017): 80. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.4236/jbm.2017.511009